Clostridium Difficile Infection (CDI) Study
Effective treatment of C. diff infections is critical, but how do we prevent the problem of recurrences?
Recurrence of Clostridium difficile infection (CDI) is a key unmet medical need in the management of CDI:
- Occurs in up to 30% of patients following initial therapy
- Significant burden on patients due to increased morbidity and diminished quality of life
- Associated with an increased risk of further recurrent episodes and an increase in severity
Ridinilazole is designed specifically to target the C. diff bacteria, which could potentially mean less damage to the gut and a reduced chance of another C. diff infection.
By targeting C. diff specifically, ridinilazole may be less disruptive to the healthy balance of the gut, that could potentially lead to a lower chance of repeat c. diff infections.
There are no costs for you to participate. If this study is a good fit, you will receive all study-related care, including medical tests, stool tests to confirm eligibility, clinical care, and investigational study drug, all at no cost to you.
Your participation will last for approximately 3 months with about 6 in-person study visits. Participation is completely voluntary and you may discontinue at any time.
If you are interested in participating in our Clostridium Difficile Infection (CDI) study, please fill out the form below or call us at 469-297-3074.
Please provide the following information so that we can contact you regarding enrolling in our current and upcoming studies. Provide only information you feel comfortable transmitting to our secure website via the internet. Your information will NOT be shared with anyone else and will only be used to contact you regarding potential involvement in our studies and for sending you study related newsletters and mailings.